The first drug that can slow the rate of decline in Alzheimer’s patients has been found. The experimental drug, called lecanemab, is an antibody that targets the toxic clumps of amyloid protein associated with the mind-robbing disease. While these results are cause for celebration, there are still significant questions about its safety and rollout.
The full results of the phase 3 lecanemab drug trial (the final stage of testing in humans) have been published in the New England Journal of Medicine. The trial showed that patients receiving the drug had a 27% slower disease progression than those receiving a placebo after 18 months of treatment.
Overall, this is good news. For the first time, we have a potential treatment that has a demonstrated effect on both the symptoms and underlying pathology of Alzheimer’s disease. These results are a breakthrough in the search for treatments for this devastating disease and give a strong indication that the course of the disease can be altered.
But the results paint a mixed picture for those with Alzheimer’s. On one hand, this is the first drug that has been shown to have any effect on slowing the progression of the disease. On the other hand, the apparent effects are slight and the risks are not inconsiderable.
Subscriber Only Stories
About 1,800 people with early-stage Alzheimer’s took part in the global trial. The participants were randomly assigned to receive either lecanemab or placebo intravenously every two weeks. The study was “double blind”, meaning neither the participants nor the researchers knew who was receiving the experimental drug and who was receiving the placebo until the end of the trial.
Throughout the study, the participants’ disease progression was tracked using the clinical dementia rating scale, which scores the patient on cognition and ability to live independently. The participants’ brains were also scanned for the two proteins commonly associated with Alzheimer’s disease: amyloid and tau.
Alzheimer’s scores in both groups worsened during the 18 months of the study, but the rate of decline was slower in those receiving the lecanemab. Also, the magnitude of the slowing, while statistically significant (not likely to be due to chance) was small – a 0.45 reduction on an 18-point scale.
Some experts are concerned that this effect may not be clinically meaningful. In a statement to the Science Media Centre, Rob Howard, professor of old age psychiatry at UCL, said that “none of the reported results, including the primary outcome, reached accepted levels of improvement to constitute a clinically meaningful treatment effect”.
The success of lecanemab was also measured by the amount of amyloid and tau protein in those on the experimental drug compared with those receiving the placebo infusion. The results showed a reduction in these proteins in those receiving lecanemab.
Indeed, the levels of brain amyloid were reduced to below the threshold needed for a positive Alzheimer’s diagnosis. However, markers of brain cell death were unaffected, indicating that amyloid in Alzheimer’s disease is just one mechanism in a complicated disease landscape.
About one in four participants (26.6%) in the lecanemab group experienced brain swelling or a bleed on the brain (which can be both minor or major). STAT, a medical news website, reported that a man died of a brain haemorrhage after receiving lecanemab, citing a possible interaction with his blood thinning medication.
A short while later, the journal Science reported a second death of a trial patient, also after receiving treatment for a stroke. However, the drug’s developer, Eisa, told Science: “All the available safety information indicates that lecanemab therapy is not associated with an increased risk of death overall or from any specific cause.
Nevertheless, given the possibility that patients may be on the drug for the rest of their lives, more research is needed on safety and interactions with existing medications.
It’s also important to find out how long-lived the improvements in cognition are, and whether the drug continues to slow the rate of decline, or if the results plateau – or even decline.
It should be noted that only patients who had a sufficient level of amyloid detected in the brain or spinal fluid – which requires a PET brain scan or an invasive lumbar puncture – were eligible to take part in this phase 3 trial. In the UK, Alzheimer’s is currently diagnosed via an interview with a doctor. Dr Susan Kohlhaas, director of research at Alzheimer’s Research UK, says the NHS is not ready for a new era of dementia treatment.
Restructuring NHS dementia services to provide routine and timely PET scans or lumbar punctures would be a costly and lengthy process.
Based on previous results, Eisai applied to the US drug regulator (the Food and Drug Administration) for accelerated approval of their drug. A decision is expected by January 6 2023. If accelerated approval is granted by the regulator, these latest results will probably support an application for full approval.
RSV, influenza numbers dropping in Manitoba | CTV News – CTV News Winnipeg
While the number of RSV cases continues to be higher than influenza numbers in the province, the latest data shows both viruses are decreasing.
For the week of Jan. 15 to 21, there were 105 RSV detections with a test positivity rate of 8.3 per cent. That was down from 8.7 per cent the previous week when there were 131 detections.
Influenza A remains low in Manitoba, with just 10 cases reported during the week for a test positivity rate of 0.8 per cent, down from 18 cases and 1.9 per cent in the week prior.
The province said the influenza test positivity rate is below the national average, which is 1.3 per cent.
Two people were admitted to hospital with influenza.
“Overall, influenza activity this season started to increase earlier than would be expected and is now below expected levels for this time of year,” the province said in its weekly report.
A graph showing the number of positive tests for respiratory viruses in the Manitoba. Jan. 27, 2023. (Source: Manitoba Health)
Looking at COVID numbers, there were 59 new cases, down from 122 the week before.
The positivity rate is at 11.3 per cent, which drop by an entire percentage point compared to the previous week.
There were seven hospital admissions as well according to the province.
“Wastewater surveillance data from January indicated sustained activity of COVID-19 in Winnipeg and Brandon at lower levels,” the province said.
Cognitive function during ECT in young adults with TRD | NDT – Dove Medical Press
Depressive disorder is common, debilitating, and significantly impacts the quality of life of affected individuals.1,2 There have been many studies on depression in children, adolescents and the elderly3–8 but relatively few in young adults,9–11 despite them having different social and neurobiological profiles.12,13 Almost 40% of patients experience their first episode of depression before 20 years of age.2 Their clinical course tends to fluctuate, with multiple recurrences in the context of life transitions.12
Depressive disorder that does not respond satisfactorily to treatment is referred to as treatment-resistant depression (TRD).14 Although TRD episodes are most commonly associated with major depressive disorder, they are also seen in the depressed phase of bipolar disorder;15 indeed, responses are not sustained in over 30% of individuals receiving treatment for unipolar depression (UPD) or bipolar depression (BPD).16–18 TRD is therefore a significant public health problem characterized by extensive disability, increased suicide attempts, and higher medical costs.16,19
Electroconvulsive therapy (ECT) has been used in clinical practice for over 80 years and is widely considered the most reliable therapy for TRD.20–22 ECT is associated with a reduced risk of suicide in the year after discharge.23 While there is strong evidence supporting the efficacy of ECT in middle-aged and older adults,24,25 little is known about its efficacy and cognitive side-effects in younger adults (aged 18–30) with TRD. Previous studies have suggested that ECT in young adults improves clinical outcomes during the acute treatment phase.26,27 Since TRD and non-TRD may differ clinically and biologically,28,29 it still needs to be clarified whether young adult with TRD adequately respond to ECT, and the side-effects and prognosis require characterization.
This study therefore had the primary objective of establishing the clinical effectiveness, speed of response, and cognitive outcomes of ECT in young adult patients with TRD. The exploratory objective was to investigate differences in ECT responses in young adults with UPD and BPD. To better answer the primary objective, we used repeated evaluation after each ECT to detail the changes in depressive symptoms and cognitive function during the entire ECT process.
Materials and Methods
This longitudinal observational trial was conducted at Renmin Hospital of Wuhan University (Mental Health Center of Hubei Province, Wuhan, Hubei, China) in accordance with the Declaration of Helsinki (revised edition, 2013).30 The Human Ethics Committee of Renmin Hospital of Wuhan University approved the study protocol. Patients or their legal guardians provided informed consent and could withdraw from the trial at any time for any reason. This report follows the STROBE statement.31
We recruited 41 patients to Cohort 1, the “main” cohort. Routine symptom and detailed cognitive function examinations were performed at baseline, after the entire ECT course, and one month later. To map the detailed trajectory of symptoms and subjective memory impairment (SMI) during ECT treatment, depressive symptom and SMI evaluations were performed after each ECT session.
Cohort 2 was used to detect changes in objective memory function with ECT and represented a 23-patient subset of Cohort 1. The forward digital span test (FDST),32 a simple and widely used tool of verbal short-term and working memory, was assessed after each ECT session. Considering potential practice effects, we recruited 15 healthy controls (HCs) matched for age, sex, and years of education, who received twelve FDSTs at the same test frequency (three times per week) as a longitudinal benchmark. Figure 1 shows the trial flow chart and study design.
Participants and Inclusion and Exclusion Criteria
Sixty-two inpatients were recruited from March 1st, 2021 to January 31st, 2022. The inclusion criteria were (1) participants aged between 18 and 30 years; (2) ability to provide informed consent; (3) meeting ICD-1033 criteria for the diagnosis of major depression or bipolar disorder current episode depressive, with or without psychotic features (F31.3, F31.4, F31.5, F32, F33) using the Mini International Neuropsychiatric Interview (MINI);34 (4) meeting the definition of TRD: patients with UPD required a minimum of two prior treatment failures and confirmation of prior adequate dose and duration,15 while patients with BPD required no response to treatment after 12 weeks of treatment or a well-documented failure to respond to at least two trials of antidepressants or an antidepressant and a mood stabilizer;35 and (5) scored ≥20 on the Montgomery-Äsberg Depression Rating Scale (MADRS).36 We excluded patients if they: (1) failed to respond to earlier ECT; (2) had received ECT over the previous three months; (3) patients with manic episodes and mixed characteristics of BPD or scored ≥6 on the Young Manic Rating Scale (YMRS);37 (4) had a lifetime diagnosis of unstable, serious comorbidities or a history of epilepsy; (5) were pregnant or women without adequate contraception; and (6) were in other clinical studies or were unsuitable for participation as assessed by the investigators.
Age-, sex-, and education-matched HCs were recruited through advertisements. They were required to be in good physical health with no personal or first-degree family history of a psychiatric disorder, significant medical illness, psychotropic medication use, or use of other medications that could interfere with neuropsychological function.
All participants received a standard pre-ECT clinical assessment including a full physical examination, laboratory analyses, electrocardiogram, electroencephalogram (EEG), and monitoring for any risks or contraindications to anesthesia and/or ECT. All individuals included in the trial did not have any clinically significant abnormalities on this assessment. Patients received bitemporal electrode placement ECT which was performed three times per week using a Thymatron IV device (Somatics, LLC). Seizure threshold was determined at the first ECT session starting at a dose level of 50mC (or 10% of machine energy) and titrated upwards till a seizure of at least 15s was induced. Subsequent ECT treatments were administered at 1.5 times seizure threshold (or one level higher).38 General anesthesia was induced with propofol (about 2 mg/kg) and myorelaxation with succinylcholine (about 1 mg/kg) and atropine (0.5 mg) before each session. Doses of propofol and succinylcholine were adjusted as needed in subsequent sessions. Orientation recovery tests after each ECT session were used to measure recovery. The decision to discontinue ECT was made by the patient’s psychiatrist after considering 1) reduced potential benefit of ECT; 2) side effects; 3) completed 12 ECT sessions; 4) patient preference; and 5) other medical considerations.
Individualized pharmacological regimens were determined by the patients’ psychiatrists. Patients maintained their previously prescribed antidepressants and antipsychotics during the trial. Anticonvulsant drugs, mood stabilizers, and benzodiazepines were discontinued during the entire course of ECT. Single-dose short half-life benzodiazepines were used as necessary when patients became agitated or felt anxious. When patients suffered from insomnia, nonbenzodiazepines were temporarily prescribed.
Measurement Tools and Visit Schedule
The MADRS was used to evaluate depressive symptoms and was performed at baseline, after each ECT session, and at one-month follow-up. A response was defined as a decrease in total MADRS score >50% from baseline to the end of treatment, and remission was defined as a total MADRS score <10 at the end of the treatment.39 The MADRS was also divided into four factors: 1) cognitive-pessimism; 2) affective; 3) cognitive-anxiety; and 4) vegetative.40 The Hamilton Anxiety Rating Scale (HAMA)41 was used to evaluate the anti-anxiety effect of ECT and was performed at baseline, after the course of ECT, and at one-month follow-up. The HAMA was also divided into somatic anxiety and psychic anxiety.
Any adverse events (AEs)/serious AEs (SAEs) or patients who dropped out for any reason were recorded.
In Cohort 1, the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)42 was performed at baseline, after the course of ECT, and at one-month follow-up to assess objective cognitive function. SMI was assessed with the cognitive component of the Columbia Subjective Side Effects Schedule (CSSES)43 after each ECT: “have you had memory problems since ECT?” This item was scored on a 4-point Likert-type scale where 0 = none, 1 = mild, 2 = moderate, and 3 = severe.
Objective memory function changes were assessed in Cohort 2. Given that most cognitive tests are complex and can take a long time to perform, tests should be simple and reliable to perform. Therefore, the FDST was chosen to evaluate memory function after each ECT session. Twelve FDSTs were performed on HCs at the same test frequency (three times per week) to provide a longitudinal benchmark.
All assessments in patients were administered 24 hours after every ECT session to avoid possible acute treatment effects.
The sample size was calculated using G*Power software (ver. 184.108.40.206).44 We expected to detect a moderate effect size (Cohen’s f = 0.25) of MADRS in seven visits (the mean number of ECT treatment is approximately six plus a baseline visit) with a power of 0.85, α of 0.05 (two-sided), and obtained a sample size of 42.
Longitudinal analyses did not require input of missing values, because the statistical methods (mixed model for repeated measures (MMRM) and cumulative link mixed model for repeated ordinal outcomes (CLMM)) could accommodate missing data.
For baseline comparisons, continuous demographic and clinical characteristics were compared using Welch’s two-sample t-test, and categorical characteristics were analyzed using Fisher’s exact test.
The primary outcome was the change in MADRS at post-treatment visit from baseline. Secondary outcomes were changes in the MADRS subscales, HAMA and its subscales. MMRM analyses were performed to estimate the dynamics of these continuous outcomes and compare the between-subgroup differences between the UPD and BPD subgroups. In general, the MMRM model included subgroup, visit (as a categorical variable), and the subgroup*visit interaction as fixed factors. Baseline values, fluoxetine, and chlorpromazine equivalent dose were included as covariates to control for potential bias from baseline status and the effect of pharmacotherapy. An unstructured covariance matrix will be used to model the within-subject correlation, and the Kenward-Roger approximation method was used to calculate the denominator degrees of freedom. Treatment effects were reported using MMRM least squares (LS) means and associated 95% confidence intervals (95% Cis). Pair-wise comparisons were adjusted using Tukey’s method.
For RBANS and FDST, similar MMRM analyses were also performed. As SMI was an ordinal variable, CLMM was performed, subgroup, visit, and the subgroup*visit interaction as included as fixed factors, and odds ratios (Ors) and their 95% Cis were used to examine whether the change in SMI increased with ECT treatment. Age, charge, and pulse width45,46 were included as covariates in both MMRM and CLMM to control for potential confounders.
All statistical tests were carried out using R version 4.1.0 (R Project for Statistical Computing) within RStudio version 1.4.1106 (RStudio) for Windows. LmerTest package47 was used for MMRM analyses, ordinal package48 was used for CLMM, effectsize package49 was used to calculate the effect sizes, and ggplot2 package50 was used for visualization.
Participant Flow and Characteristics
Figure 1 shows the participant flow. For the main cohort, 62 patients were enrolled: 20 screen failures were excluded after entry, and 42 patients completed the visits after ECT treatment. Unfortunately, one patient withdrew informed consent after the trial completed; as a result, the final sample size for analysis was 41. Twenty-three patients also participated in Cohort 2. Descriptive data are presented in Table 1, and Table S1 presents the comparisons between the UPD and BPD subgroups.
Table 1 Descriptive Data of Included Subjects
Forty-one participants received a total of 272 ECTs, and 31 (75.6%) completed the one-month follow-up visit. Six patients ended ECT without a clinical response and less than 12 treatments due to fever, headache, and dissatisfaction with the efficacy. Ten patients dropped out at one-month follow-up. There were no significant differences in response/remission rates at the post-ECT visit between completers and dropout patients (see Table S2).
The LS mean change in total MADRS score from baseline to the end of treatment was −24.9 (95% CI = −27.9, −21.9), Cohen’s f = 1.19 (90% CI = 1.02, 1.31). Thirty-five (85.4%) and 12 (29.3%) patients met the criteria for response and remission after ECT. In subgroup analyses, the difference in response rate and remission rate between patients with UPD (80.0% and 28.0%) and BPD (93.8% and 31.3%) were non-significant (Fisher’s exact test, p = 0.376 and 1.000). Anxiety mirrored the depressive symptoms. In subgroup analyses, the antidepressant and anti-anxiety effects of CBT were similar. The reduction in total MADRS total score and its two subscales (cognitive pessimism and affective) and the HAMA subscale (somatic anxiety) were slightly but significantly larger in the UPD subgroup than the BPD subgroup at the follow-up visit (all adjusted P-values (Tukey’s method) <0.05, see Table S3). However, BPD patients received significantly more ECT sessions than the UPD patients.
At one-month follow-up, 16/31 (51.6%) and 8/31 (25.8%) patients met the criteria for response and remission. In subgroup analyses, the differences in response rates and remission rates between patients with UPD (57.9% and 36.8%) and BPD (41.7% and 8.3%) were not significant (Fisher’s exact test, p = 0.473 and 0.199). Details of the MADRS, HAMA, and their subscale estimates are presented in Table 2, Figure 2, and Figures S1 and S2.
Table 2 Estimated Least Squares Mean Effect Size of MADRS and HAMA Based on MMRM
Figure 2 MADRS and HAMA at baseline, post-ECT, and at follow-up. (A) Total Montgomery-Äsberg Depression Rating Scale (MADRS) score and (B) total Hamilton Anxiety Rating Scale (HAMA) score of Cohort 1 at baseline, post electroconvulsive therapy (ECT), and at follow-up. The pairwise comparisons between the three visits are all statistically significant (details are shown in Table 2).
Abbreviations: UPD, unipolar depression; BPD, bipolar depression.
As shown in Figure 3, Table S3, and Figure S3, the effect size of MADRS trajectories over the course of ECT was large. There were steep trajectories for MADRS and its four subscales after 3–4 ECTs, and the reduction from baseline was statistically significant after the first ECT. In subgroup analyses, the MADRS trajectories for both UPD and BPD patients were similar, except for the “vegetative” subscale, whose reduction in the UPD subgroup was significantly quicker than in the BPD group at visits 2–6 (adjusted p-values (Tukey’s method) <0.05, see Table S3).
Figure 3 Trajectory of MADRS. The Montgomery-Äsberg depression rating scale (MADRS) total score trajectory during the course of electroconvulsive therapy (ECT) treatment in Cohort 1. The reductions in total MADRS scores at each post-ECT visit from baseline are all statistically significant, but the between-subgroup differences (unipolar depression (UDP) versus bipolar depression (BPD)) were not significant (see Table S4).
As shown in Table 3 and Figure 4, at the post-ECT visit, there were no significant changes in total RBANS score nor the visuospatial/constructional, language, and attention subscales. There was a significant post-ECT increase in two RBANS subscales (immediate memory and delayed memory). At one-month follow-up, there was a significant increase in total RBANS score and the immediate memory, attention, and delayed memory subscales. Subgroup analysis suggested that the UPD subgroup contributed most to these changes, but the between-subgroup differences were not statistically significant after correction.
Table 3 Estimated Least Squares Mean Effect Size of RBANS Based on MMRM
Figure 4 RBANS at baseline, post-ECT, and at follow-up. (A) Total Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) score and (B–F) RBANS subscales for Cohort 1 at baseline, post electroconvulsive therapy (ECT), and at follow-up (details are shown in Table 3).
For SMI, 34 patients reported varying degrees of subjective cognitive impairment at different visits, and 19 patients reported persistent SMI at the follow-up visit. In the CLMM analysis, SMI significantly increased during ECT (OR = 3.20 (95% CI = 2.38, 4.28; Z = 7.817, p < 0.001)).
With respect to the trajectory of objective memory function during ECT, as there was a significant practice effect of FDST in the HC group, we focused not only on the within-group change but also the interaction effect size between groups. As shown in Figure 5, Figure S4, and Tables S5 and S6, the between-group differences were non-significant at most visits, except for visits 7 and 11. However, in subgroup analyses, the between-subgroup differences were non-significant after correction.
Figure 5 Trajectory of FDST. The Digital Span Test (FDST) trajectory during electroconvulsive therapy (ECT) treatment in Cohort 2. The between-group differences are non-significant at most visits, except for visits 7 and 11 (see Tables S5 and S6).
No SAEs occurred during the trial. One hundred and ten common AEs were recorded, with the top AEs being headaches (61 events), muscle aches (28 events), and nausea (7 events).
Data Availability Statement
The data that support the findings of this study are available from the corresponding author, upon reasonable request.
This is the first trial presenting detailed observations of the efficacy, speed of response, and cognitive changes of ECT in young adults with TRD. Our trial had two main findings. First, the effect size of ECT was large, with 85.4% of patients with TRD responding to an acute course of ECT and the largest improvements occurring during the first 3–4 ECT sessions. Second, there was a discrepancy between subjective and objective cognitive outcomes during ECT, with patients presenting with more subjective than objective cognitive adverse effects of ECT.
The severity of depression and anxiety was clinically and statistically reduced after ECT. These results were consistent over different outcomes including MADRS subscales and HAMA, and the difference in efficacy between UPD and BPD was non-significant. These findings are consistent with previous studies in young adults,26,27 although the current response rate (85%) was slightly higher.24,51 This may be because the patients in our trial suffered from more severe depression combined with a higher rate of psychotic symptoms, which may predict particularly good ECT responses compared with patients with mild-to-moderate depression.52
Our repeated symptom assessment revealed that the largest clinical improvements occurred during the first 3–4 ECT sessions for most patients, with a plateau of response after approximately four ECT sessions. The MADRS trajectories were similar in the UPD and BPD subgroups. This finding is consistent with previous studies showing that ECT resulted in a rapid decline in depressed symptom ratings over the early course of treatment and that the symptom change was non-linear,53,54 which might represent a common pattern of depression relief from ECT, regardless of depression type, treatment sensitivity, severity, and electrode placement. We previously proposed a simple but completely novel ECT protocol involving low-charge electrotherapy (Hybrid-ECT),55 and our pilot trial showed that Hybrid-ECT may have similar antidepressant effects but with fewer side-effects.56 We hope there will be more studies developing new ECT protocols that exploit the characteristics of the non-linear symptom relief curve.
Existing data suggest that the long-term outcomes of ECT are poor.57,58 Over half of patients with depression relapsed by one year following successful initial treatment with ECT, with the majority relapsing within the first six months.57 Our data show that nearly two-thirds of patients who respond to acute ECT relapsed after one month regardless of subtype, as previously reported.59 Although most patients received continuation pharmacotherapy, relapse rates following ECT are disappointingly high. Young adults with TRD are vulnerable to relapsing depression related to life stresses including separation, individuation, and identity formation.12 It has been reported that continuation or maintenance of ECT might prevent depression recurrence after initial response to ECT.59,60
Subjective and Objective Cognitive Function
The cognitive side-effects of ECT, especially memory impairment, have received a lot of attention.46,61–65 We evaluated subjective and objective cognitive function after every ECT and found an unexpected discrepancy between subjective and objective cognitive outcomes, similar to a recent study.64
By exploiting repeated evaluation, we found that subjective cognitive complaints significantly increased during ECT and were still present at one-month follow-up. This result is consistent with a recent study showing that the number of ECT was associated with subjective cognition: more sessions received, higher prevalence of complaints.45 Furthermore, subjective cognitive complaints did not decrease over time following treatment.45 There are several possible reasons. First, we used bitemporal ECT, which is usually considered to be associated with more cognitive effects than unilateral ECT.45 Second, younger patients with more depressive symptoms overreported cognitive impairments.64,66,67 The patients in our study were young adults who have greater access to the media and internet and who may have learned about the side-effects of ECT to negatively affect their expectations. This expectation may also have induced a “nocebo effect”, a negative effect of a pharmacological or non-pharmacological treatment due to patient expectations.68 Third, younger patients may be more concerned about cognitive deficits because they impede educational attainment and occupational and interpersonal functioning.69 In addition, patients with TRD and a longer disease course may experience more failures related to cognitive abilities, which may maintain negative self-perceptions that exacerbate their perceived cognitive difficulties.70
Conversely, for objective cognitive function, there were no significant changes after ECT treatment as measured with the total RBANS score and visuospatial/constructional, language, and attention subscales. Not only that, there was a significant and consistent increase in memory as measured by the FDST and RBANS subscales, including immediate and delayed memory. Consistent with our results, some studies have also detected improvements in several cognitive domains after ECT,61–63 although many have similarly detected acute reduced cognition.27,65,71 These conflicting results may be for several reasons. First, a brief stimulus may significantly reduce adverse cognitive effects,62,72 especially with an ultra-brief pulse of no more than 0.5 ms.61,62 Second, ECT increases hippocampal neurogenesis in adults.73–75 Young adults may have more hippocampal neurogenesis after ECT than older individuals.73 Neurogenesis-mediated inhibition reduces memory interference and enables reversal learning in both neutral and emotionally charged situations. This increased cognitive flexibility in turn may help reduce anxiety- and depression-like behaviors.74
However, the improvement in objective memory was not linear. The FDST trajectory in the TRD group had a slight “S”-shape: increasing over the first 4 visits, decreasing from visits 5–7, and then increasing again. The decrease from visits 5–7 in TDR patients may be due to a cumulative effect of repeated ECT sessions. ECT-induced neurogenesis may lead to abnormal clearance of old memories or a failure to form new memories in the hippocampus, subsequently disrupting memory processes and storage.76,77 We speculate that this may be the reason why there was a slight decline in memory in the later stages of ECT, even though objective memory after the entire course of ECT was significantly better than baseline.
Furthermore, in the follow-up phase, patients showed significantly improved objective cognition than during acute ECT in terms of total RBANS score and the immediate memory, attention, and delayed memory sub-scores. These results are in keeping with previous studies showing that working memory and some aspects of executive function improved beyond baseline after two weeks posttreatment.65,78 In short, the impact and mechanisms of ECT on memory deserve further detailed exploration.
There are limitations that mean care should be taken extrapolating our conclusions. The cognitive measurements after ECT were relatively simple, due to the difficulty in implementation and limited energy of patients. Another likely explanation for the subjective memory impairment results was that retrograde memory functioning was not assessed. This is the cognitive side effect of ECT and also limitation to the current study. Furthermore, we found a practice effect for FDST, which may counteract the cognitive impairment associated with ECT, considering the possibility of drop-out at follow-up and difficulties in trial implementation, we selected age-, sex-, and education-matched HCs to adjust for the practice effect. The absence of “no-ECT” depression group is another limitation; however, given that this was a group of drug-resistant patients with limited medication changes while receiving ECT, it is unlikely that changes in antidepressant medication had significant impacts on the main results. Furthermore, about 25% of patients were lost to follow-up at one month, mainly due to the COVID-19 pandemic. We had no detailed neurological status for these patients, which could have had a major impact on cognitive status.
ECT is an effective treatment for young adults with TRD. Although there was an increase in SMI with treatment, objective impairments in cognition were not observed. We also recommend using repeated evaluation in future studies to detect subtle changes related to ECT. Clinicians can inform patients about the characteristics of cognitive adverse effects of ECT. They may experience more subjective cognition problems than objective cognition. On this basis, they may need more subjective cognitive training.
We would like to thank Dezhen Su, Cai Nan, Li Wang, Cheng Chen, Maolin Hu, Gui Gui, Chang Shu, Hao Liu, Xin Guo, Baoli Zhang, Junhui Guo and other medical staff from the Department of Psychiatry in Renmin Hospital of Wuhan University, for their assistance of participants recruitment. We also acknowledge language editorial assistance from Nextgenediting.
This work was supported by grants from the National Natural Science Foundation of China (grant number: U21A20364) and the National Key R&D Program of China (grant number: 2018YFC1314600).
The authors declare that there is no conflict of interest in this work.
1. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396(10258):1204–1222. doi:10.1016/S0140-6736(20)30925-9
2. Malhi GS, Mann JJ. Depression. Lancet. 2018;392(10161):2299–2312. doi:10.1016/S0140-6736(18)31948-2
3. Alexopoulos GS. Depression in the elderly. Lancet. 2005;365(9475):1961–1970. doi:10.1016/S0140-6736(05)66665-2
4. Wang S, Blazer DG. Depression and cognition in the elderly. Annu Rev Clin Psychol. 2015;11:331–360. doi:10.1146/annurev-clinpsy-032814-112828
5. Taylor WD. Clinical practice. Depression in the elderly. N Engl J Med. 2014;371(13):1228–1236. doi:10.1056/NEJMcp1402180
6. Cummings CM, Caporino NE, Kendall PC. Comorbidity of anxiety and depression in children and adolescents: 20 years after. Psychol Bull. 2014;140(3):816–845. doi:10.1037/a0034733
7. Werner-Seidler A, Perry Y, Calear AL, Newby JM, Christensen H. School-based depression and anxiety prevention programs for young people: a systematic review and meta-analysis. Clin Psychol Rev. 2017;51:30–47. doi:10.1016/j.cpr.2016.10.005
8. Hazell P. Updates in treatment of depression in children and adolescents. Curr Opin Psychiatry. 2021;34(6):593–599. doi:10.1097/YCO.0000000000000749
9. Legha RK, Gerbasi ME, Smith Fawzi MC, et al. A validation study of the Zanmi Lasante Depression Symptom Inventory (ZLDSI) in a school-based study population of transitional age youth in Haiti. Confl Health. 2020;14:13. doi:10.1186/s13031-020-0250-9
10. Jain JP, Santos G-M, Hao J, et al. The syndemic effects of adverse mental health conditions and polysubstance use on being at risk of clinical depression among marginally housed and homeless transitional age youth living in San Francisco, California. PLoS One. 2022;17(3):e0265397. doi:10.1371/journal.pone.0265397
11. Hakulinen C, Musliner KL, Agerbo E. Bipolar disorder and depression in early adulthood and long-term employment, income, and educational attainment: a nationwide cohort study of 2,390,127 individuals. Depress Anxiety. 2019;36(11):1080–1088. doi:10.1002/da.22956
12. Chan V, Moore J, Derenne J, Fuchs DC. Transitional age youth and college mental health. Child Adolesc Psychiatr Clin N Am. 2019;28(3):363–375. doi:10.1016/j.chc.2019.02.008
13. Martel A, Fuchs DC. Transitional age youth and mental illness – influences on young adult outcomes. Child Adolesc Psychiatr Clin N Am. 2017;26(2):xiii–xvii. doi:10.1016/j.chc.2017.01.001
14. Thase ME, Rush AJ. When at first you don’t succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997;58(Suppl 13):23–29.
15. Gaynes BN, Lux L, Gartlehner G, et al. Defining treatment-resistant depression. Depress Anxiety. 2020;37(2):134–145. doi:10.1002/da.22968
16. Halaris A, Sohl E, Whitham EA. Treatment-resistant depression revisited: a glimmer of hope. J Pers Med. 2021;11(2):Feb. doi:10.3390/jpm11020155
17. Voineskos D, Daskalakis ZJ, Blumberger DM. Management of treatment-resistant depression: challenges and strategies. Neuropsychiatr Dis Treat. 2020;16:221–234. doi:10.2147/NDT.S198774
18. Perlis RH, Ostacher MJ, Patel JK, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry. 2006;163(2):217–224. doi:10.1176/appi.ajp.163.2.217
19. Galecki P, Samochowiec J, Mikulowska M, Szulc A. Treatment-resistant depression in Poland-epidemiology and treatment. J Clin Med. 2022;11(3):480. doi:10.3390/jcm11030480
20. Kellner CH, Greenberg RM, Murrough JW, Bryson EO, Briggs MC, Pasculli RM. ECT in treatment-resistant depression. Am J Psychiatry. 2012;169(12):1238–1244. doi:10.1176/appi.ajp.2012.12050648
21. Kolar D. Current status of electroconvulsive therapy for mood disorders: a clinical review. Evid Based Ment Health. 2017;20(1):12–14. doi:10.1136/eb-2016-102498
22. Kirov G, Jauhar S, Sienaert P, Kellner CH, McLoughlin DM. Electroconvulsive therapy for depression: 80 years of progress. Br J Psychiatry. 2021;219(5):594–597. doi:10.1192/bjp.2021.37
23. Kaster TS, Blumberger DM, Gomes T, Sutradhar R, Wijeysundera DN, Vigod SN. Risk of suicide death following electroconvulsive therapy treatment for depression: a propensity score-weighted, retrospective cohort study in Canada. Lancet Psychiatry. 2022;9(6):435–446. doi:10.1016/S2215-0366(22)00077-3
24. Haq AU, Sitzmann AF, Goldman ML, Maixner DF, Mickey BJ. Response of depression to electroconvulsive therapy: a meta-analysis of clinical predictors. J Clin Psychiatry. 2015;76(10):1374–1384. doi:10.4088/JCP.14r09528
25. Jiang X, Xie Q, Liu LZ, Zhong BL, Si L, Fan F. Efficacy and safety of modified electroconvulsive therapy for the refractory depression in older patients. Asia Pac Psychiatry. 2020;12(4):e12411. doi:10.1111/appy.12411
26. Benson NM, Seiner SJ, Bolton P, et al. Acute phase treatment outcomes of electroconvulsive therapy in adolescents and young adults. J ECT. 2019;35(3):178–183. doi:10.1097/YCT.0000000000000562
27. Luccarelli J, McCoy TH, Uchida M, Green A, Seiner SJ, Henry ME. The efficacy and cognitive effects of acute course electroconvulsive therapy are equal in adolescents, transitional age youth, and young adults. J Child Adolesc Psychopharmacol. 2021;31(8):538–544. doi:10.1089/cap.2021.0064
28. Akil H, Gordon J, Hen R, et al. Treatment resistant depression: a multi-scale, systems biology approach. Neurosci Biobehav Rev. 2018;84:272–288. doi:10.1016/j.neubiorev.2017.08.019
29. Buoli M, Capuzzi E, Caldiroli A, et al. Clinical and biological factors are associated with treatment-resistant depression. Behav Sci. 2022;12(2):Feb. doi:10.3390/bs12020034
30. World Medical Association. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–2194. doi:10.1001/jama.2013.281053
31. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Bull World Health Organ. 2007;85:867–872. doi:10.2471/BLT.07.045120
32. Grégoire J, Van Der Linden M. Effect of age on forward and backward digit spans. Aging Neuropsychol Cogn. 1997;4(2):140–149. doi:10.1080/13825589708256642
33. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. World Health Organization; 1992.
34. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(20):22–33;quiz 34–57.
35. Fountoulakis KN, Yatham LN, Grunze H, et al. The CINP guidelines on the definition and evidence-based interventions for treatment-resistant bipolar disorder. Int J Neuropsychopharmacol. 2020;23(4):230–256. doi:10.1093/ijnp/pyz064
36. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–389. doi:10.1192/bjp.134.4.382
37. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429–435. doi:10.1192/bjp.133.5.429
38. Enns MW, Reiss JP, Chan P. Electroconvulsive therapy. Can J Psychiatry. 2010;55(6):S1.
39. van Duist M, Spaans HP, Verwijk E, Kok RM. ECT non-remitters: prognosis and treatment after 12 unilateral electroconvulsive therapy sessions for major depression. J Affect Disord. 2020;272:501–507. doi:10.1016/j.jad.2020.03.134
40. Craighead WE, Evans DD. Factor analysis of the Montgomery-asberg depression rating scale. Depression. 1996;4(1):31–33. doi:10.1002/(SICI)1522-7162(1996)4:1<31::AID-DEPR3>3.0.CO;2-I
41. Thompson E. Hamilton Rating Scale for Anxiety (HAM-A). Occup Med. 2015;65(7):601. doi:10.1093/occmed/kqv054
42. Randolph C, Tierney MC, Mohr E, Chase TN. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 1998;20(3):310–319. doi:10.1076/jcen.20.3.310.823
43. Sackeim HA, Ross FR, Hopkins N, Calev L, Devanand DP. Subjective side effects acutely following ECT: associations with treatment modality and clinical response. Convuls Ther. 1987;3(2):100–110.
44. Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009;41(4):1149–1160. doi:10.3758/BRM.41.4.1149
45. Semkovska M, Knittle H, Leahy J, Rasmussen JR. Subjective cognitive complaints and subjective cognition following electroconvulsive therapy for depression: a systematic review and meta-analysis. Aust N Z J Psychiatry. 2022;48674221089231. doi:10.1177/00048674221089231
46. Vann Jones S, McCollum R. Subjective memory complaints after electroconvulsive therapy: systematic review. BJPsych Bull. 2019;43(2):73–80. doi:10.1192/bjb.2018.45
47. Kuznetsova A, Brockhoff PB, Christensen RH. lmerTest package: tests in linear mixed effects models. J Stat Softw. 2017;82:1–26. doi:10.18637/jss.v082.i13
48. Christensen RHB. Ordinal—regression models for ordinal data. R Package Version. 2015;28:2015.
49. Ben-Shachar MS, Lüdecke D, Makowski D. effectsize: estimation of effect size indices and standardized parameters. J Open Source Softw. 2020;5(56):2815. doi:10.21105/joss.02815
50. Wickham H. ggplot2. In: Wiley Interdisciplinary Reviews: Computational Statistics. Springer; 2011:180–185.
51. Steinholtz L, Reutfors J, Brandt L, et al. Response rate and subjective memory after electroconvulsive therapy in depressive disorders with psychiatric comorbidity. J Affect Disord. 2021;292:276–283. doi:10.1016/j.jad.2021.05.078
52. Petrides G, Fink M, Husain MM, et al. ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE. J ECT. 2001;17(4):244–253. doi:10.1097/00124509-200112000-00003
53. Kellner CH, Knapp R, Husain MM, et al. Bifrontal, bitemporal and right unilateral electrode placement in ECT: randomised trial. Br J Psychiatry. 2010;196(3):226–234. doi:10.1192/bjp.bp.109.066183
54. Ostergaard SD, Speed MS, Kellner CH, et al. Electroconvulsive therapy (ECT) for moderate-severity major depression among the elderly: data from the pride study. J Affect Disord. 2020;274:1134–1141. doi:10.1016/j.jad.2020.05.039
55. Rong H, Xu SX, Zeng J, et al. Study protocol for a parallel-group, double-blinded, randomized, controlled, noninferiority trial: the effect and safety of hybrid electroconvulsive therapy (Hybrid-ECT) compared with routine electroconvulsive therapy in patients with depression. BMC Psychiatry. 2019;19(1):344. doi:10.1186/s12888-019-2320-3
56. Zhang J-Y, Xu S-X, Zeng L, et al. Improved safety of hybrid electroconvulsive therapy compared with standard electroconvulsive therapy in patients with major depressive disorder: a randomized, double-blind, parallel-group pilot trial. Front Psychiatry. 2022;13:1062.
57. Jelovac A, Kolshus E, McLoughlin DM. Relapse following successful electroconvulsive therapy for major depression: a meta-analysis. Neuropsychopharmacology. 2013;38(12):2467–2474. doi:10.1038/npp.2013.149
58. Fekadu A, Wooderson SC, Markopoulo K, Donaldson C, Papadopoulos A, Cleare AJ. What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies. J Affect Disord. 2009;116(1–2):4–11. doi:10.1016/j.jad.2008.10.014
59. Omori W, Itagaki K, Kajitani N, et al. Shared preventive factors associated with relapse after a response to electroconvulsive therapy in four major psychiatric disorders. Psychiatry Clin Neurosci. 2019;73(8):494–500. doi:10.1111/pcn.12859
60. Elias A, Phutane VH, Clarke S, Prudic J. Electroconvulsive therapy in the continuation and maintenance treatment of depression: systematic review and meta-analyses. Aust N Z J Psychiatry. 2018;52(5):415–424. doi:10.1177/0004867417743343
61. Sienaert P, Vansteelandt K, Demyttenaere K, Peuskens J. Randomized comparison of ultra-brief bifrontal and unilateral electroconvulsive therapy for major depression: cognitive side-effects. J Affect Disord. 2010;122(1–2):60–67. doi:10.1016/j.jad.2009.06.011
62. Sackeim HA, Prudic J, Nobler MS, et al. Effects of pulse width and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. Brain Stimul. 2008;1(2):71–83. doi:10.1016/j.brs.2008.03.001
63. Verwijk E, Comijs HC, Kok RM, et al. Short- and long-term neurocognitive functioning after electroconvulsive therapy in depressed elderly: a prospective naturalistic study. Int Psychogeriatr. 2014;26(2):315–324. doi:10.1017/S1041610213001932
64. Hammershoj LG, Petersen JZ, Jensen HM, Jorgensen MB, Miskowiak KW. Cognitive adverse effects of electroconvulsive therapy: a discrepancy between subjective and objective measures? J ECT. 2022;38(1):30–38. doi:10.1097/YCT.0000000000000797
65. Semkovska M, McLoughlin DM. Objective cognitive performance associated with electroconvulsive therapy for depression: a systematic review and meta-analysis. Biol Psychiatry. 2010;68(6):568–577. doi:10.1016/j.biopsych.2010.06.009
66. Petersen JZ, Porter RJ, Miskowiak KW. Clinical characteristics associated with the discrepancy between subjective and objective cognitive impairment in depression. J Affect Disord. 2019;246:763–774. doi:10.1016/j.jad.2018.12.105
67. Srisurapanont M, Mok YM, Yang YK, et al. Cognitive complaints and predictors of perceived cognitive dysfunction in adults with major depressive disorder: findings from the cognitive dysfunction in asians with depression (CogDAD) study. J Affect Disord. 2018;232:237–242. doi:10.1016/j.jad.2018.02.014
68. Pouillon L, Socha M, Demore B, et al. The nocebo effect: a clinical challenge in the era of biosimilars. Expert Rev Clin Immunol. 2018;14(9):739–749. doi:10.1080/1744666X.2018.1512406
69. Jaeger J, Berns S, Uzelac S, Davis-Conway S. Neurocognitive deficits and disability in major depressive disorder. Psychiatry Res. 2006;145(1):39–48. doi:10.1016/j.psychres.2005.11.011
70. Beck AT. Cognitive Therapy and the Emotional Disorders. Penguin; 1979.
71. Nuninga JO, Claessens TFI, Somers M, et al. Immediate and long-term effects of bilateral electroconvulsive therapy on cognitive functioning in patients with a depressive disorder. J Affect Disord. 2018;238:659–665. doi:10.1016/j.jad.2018.06.040
72. Youssef NA, Sidhom E. Feasibility, safety, and preliminary efficacy of Low Amplitude Seizure Therapy (LAP-ST): a proof of concept clinical trial in man. J Affect Disord. 2017;222:1–6. doi:10.1016/j.jad.2017.06.022
73. Rotheneichner P, Lange S, O’Sullivan A, et al. Hippocampal neurogenesis and antidepressive therapy: shocking relations. Neural Plast. 2014;2014:723915. doi:10.1155/2014/723915
74. Anacker C, Hen R. Adult hippocampal neurogenesis and cognitive flexibility – linking memory and mood. Nat Rev Neurosci. 2017;18(6):335–346. doi:10.1038/nrn.2017.45
75. Takamiya A, Kishimoto T, Hirano J, Kikuchi T, Yamagata B, Mimura M. Association of electroconvulsive therapy-induced structural plasticity with clinical remission. Prog Neuropsychopharmacol Biol Psychiatry. 2021;110:110286. doi:10.1016/j.pnpbp.2021.110286
76. Yau SY, Li A, So KF. Involvement of adult hippocampal neurogenesis in learning and forgetting. Neural Plast. 2015;2015:717958. doi:10.1155/2015/717958
77. Frankland PW, Kohler S, Josselyn SA. Hippocampal neurogenesis and forgetting. Trends Neurosci. 2013;36(9):497–503. doi:10.1016/j.tins.2013.05.002
78. Loughran O, Finnegan M, Dud I, Galligan T, Kennedy M, McLoughlin DM. Decision-making capacity for treatment after electroconvulsive therapy for depression. J ECT. 2022;38(1):24–29. doi:10.1097/YCT.0000000000000804
Good Dental Health Essential in Sickle Cell Anemia, Study Finds |… – Sickle Cell Anemia News
Good oral health is essential in people with sickle cell anemia (SCA), according to a new study from Saudi Arabia that found that several disease-causing bacteria species — including Enterobacteriaceae — were significantly more abundant in a group of patients with poorer dental health than in those with better oral care.
“A healthy mouth has a balance of bacteria, but inadequate oral health narrows the range of bacteria, resulting in oral dysbiosis, a state in which beneficial bacteria decrease and potentially pathogenic [disease-causing] bacteria increase,” the researchers wrote.
The findings also indicated that patients with low levels of hemoglobin F — a type of hemoglobin normally produced during fetal development — had a significantly higher prevalence of harmful bacteria species than those who had higher levels of the protein.
“Our data further emphasise the importance of routine oral hygiene visits for patients with SCA,” the team wrote, adding, “This is especially important for patients with SCA and low [hemoglobin F], who have a higher probability of hospitalisation and clinical complications compared to patients with SCA and high [hemoglobin F].”
The research’s findings were reported in “Oral microbiota analyses of Saudi sickle cell anemics with dental caries,” a study published in the International Dental Journal.
Examining good versus poor dental health in SCA
Sickle cell disease (SCD) is caused by mutations in the HBB gene that lead to the production of a faulty version of hemoglobin, the protein in red blood cells that is responsible for carrying oxygen through the body. This faulty version is called hemoglobin S.
People with sickle cell anemia or SCA, the most common and often the most severe form of SCD, have two faulty gene copies encoding hemoglobin S.
Complications of dental caries or tooth decay, including acute pain, are often observed in patients with SCA — and have been associated with poor quality of life.
In a healthy mouth, different bacteria species co-exist in a balanced ratio. However, in cases of inadequate oral health, the number of beneficial bacteria decreases, while that of potentially harmful ones increases. This can lead to dental caries, which often result in cavities and other oral health problems.
“Although ample evidence indicates a causative correlation between the disruption of the oral [bacteria] and dental caries, the effect in SCA has not been investigated,” the researchers wrote.
Now, a team from the Netherlands and Saudi Arabia conducted a study to examine oral bacteria composition in people with SCA. Their aim was to compare bacteria species in patients with a high decayed, missing, and filled permanent teeth (DMTF) index — a measure of dental health — compared with others who had a low index.
In addition, they evaluated the effect of hemoglobin F levels on bacterial composition by comparing the profiles of patients with low and high levels of the protein. Fetal hemoglobin or hemoglobin F is considered a major modulator of disease severity in SCA.
This type of hemoglobin normally is found in fetuses and newborn babies, but is typically replaced by another hemoglobin variant after birth. However, hemoglobin F is more effective at transporting oxygen than its adult counterpart, and may, therefore, help to counteract the harmful effects of hemoglobin S on blood flow and oxygen transport.
In some individuals, the levels of hemoglobin F remain relatively high during childhood, and only start to decline later on in life, rather than immediately after birth.
High levels of Enterobacteriaceae bacteria found
This new study was conducted in the Eastern Province of Saudi Arabia, where the disease is highly prevalent. It included 100 patients, ages 5–12, from whom saliva was collected.
Among the patients, 27 had high dental caries — reflected by a high DMTF index of five points or more — and 73 had low dental caries, indicated by a low DMTF index of four points or fewer.
The research team identified 416 bacteria species in the patients’ samples. When analyzing their prevalence, seven were found to be significantly more abundant in patients with a high DMTF index than in those with a low index.
In addition, eight bacteria species were found to be significantly more prevalent in patients with low hemoglobin F levels compared with those with high levels of the protein.
In particular, the Enterobacteriaceae bacteria species, which have been associated with severe infections and high rates of antibiotic resistance, were found in great abundance in both patient groups, being the most significantly abundant bacteria species among those with low levels of hemoglobin F.
“It has been suggested that the presence of the Enterobacteriaceae species in the oral cavity is favoured when an individual’s immunity is compromised,” the researchers wrote, adding that “patients with SCA are immunocompromised.”
Overall, these findings indicate that Saudi SCA patients with poorer dental health and low levels of hemoglobin F have a higher predominance of harmful bacteria in their mouth.
Our data further emphasise the importance of routine oral hygiene visits for patients with SCA.
“Our results provide a valuable addition to the global microbiome reference data set in an underexamined community,” the researchers wrote, adding, “These efforts are essential and warranted given the scarcity of [bacteria composition] data in Middle Eastern populations.”
Nevertheless, a study with a large sample size evaluating how oral bacterial species can relate to dental caries in SCA patients is required, the team noted.
The researchers said their findings indicate the important of good dental health in people with sickle cell anemia, given that the bacteria species otherwise found “are thought to drive the development and progression of dental caries.”
Google's AI generated music is unsurprisingly great – MobileSyrup
Samsung Galaxy S23 Ultra: Launch Date, Specs And Twitter Reactions – AugustMan HongKong
RSV, influenza numbers dropping in Manitoba | CTV News – CTV News Winnipeg
Silver investment demand jumped 12% in 2019
Iran anticipates renewed protests amid social media shutdown
Search for life on Mars accelerates as new bodies of water found below planet’s surface
Business22 hours ago
Being Charismatic Greatly Benefits Your Job Search
Tech15 hours ago
Oppo Reno8 T 4G Sunset Orange model poses for the camera, revealing key specs – GSMArena.com news – GSMArena.com
Investment19 hours ago
Opinion: Now is the time to invest in post-secondary education – Edmonton Journal
Real eState5 hours ago
Housing market: Jason Oppenheim warns of an 'armageddon' in the real estate industry – Yahoo Finance
Art22 hours ago
Wish you could set fire to the last 3 years? A huge flaming art installation is coming to Toronto – CBC.ca
Economy15 hours ago
US inflation and consumer spending cooled in December – Al Jazeera English
Real eState15 hours ago
Real estate agents say they can't imagine working without ChatGPT now – CNN
Media9 hours ago
Trump’s Evolution on Truth Social: More QAnon, More Extremes – The New York Times